COMMUNIQUÉS West-GlobeNewswire

Children’s National launches Division of AI Research to lead the future of artificial intelligence in pediatric medicine
23/03/2026
New division will build infrastructure to bring trustworthy, clinically grounded AI to help care for kids Washington, DC, March 23, 2026 (GLOBE NEWSWIRE) -- Children’s National Hospital has launched the Division of AI [...]
Vantive Accelerates U.S. Home Therapy Transformation With New Digital and Patient Support Innovations
23/03/2026
DEERFIELD, Ill., March 23, 2026 (GLOBE NEWSWIRE) -- Vantive , a vital organ therapy company with a 70-year legacy of kidney care innovation, today announced a significant expansion of its U.S. home therapy innovation [...]
BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair
23/03/2026
SEC-Qualified Financial Expert and Life Sciences Veteran Brings 29 Years of Accounting Leadership to the Board Pompano Beach, FL, March 23, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, a leading MedTech company [...]
Cortexa Advances Commercialisation of MDMA Supply in Australia
23/03/2026
MELBOURNE, Australia, March 23, 2026 (GLOBE NEWSWIRE) -- Cortexa (Cortexa or the Company), a leading psychedelic medicines supplier, reaffirms its market leading position in FY2026 for MDMA (3,4- [...]
Tempest Therapeutics Announces Up To $6 Million Private Placement
23/03/2026
$2 million upfront with up to approximately $4 million of potential aggregate gross proceeds upon the exercise in full of warrants BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq [...]
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy
23/03/2026
MALVERN, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a [...]
ORYZON Announces U.S. Patent Grant Covering Iadademstat Combinations with Venetoclax
23/03/2026
Key combination for the treatment of first-line AML Recent data from an ongoing study in first-line AML showed a 100% overall response rate (ORR) with iadademstat in combination with venetoclax and azacitidine MADRID [...]
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services
23/03/2026
Ms. McDonough previously served as Senior Vice President of Patient Access, Analytics, and Operations at Krystal Biotech (Nasdaq: KRYS), where she helped lead the U.S. launch of VYJUVEK®, supporting its growth from FDA [...]
Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
23/03/2026
Rese-cel myositis BLA submission on track for 2027 based on a 17-patient, single arm registrational cohort design, including an outpatient dosing option No-preconditioning program enrolling in lupus and PV; anticipating [...]
Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors
23/03/2026
-- Ms. Jarrett brings nearly three decades of executive leadership in biotech, tech and finance -- -- Biotech leaders Dr. Cameron Turtle and Mike Landsittel appointed to Board of Directors -- -- Peter Harwin named [...]
Kraig Biocraft Laboratories Increases R&D Capacity, as Project Atlas Breakthroughs Creating New Spider Silk Transgenics
23/03/2026
ANN ARBOR, Mich., March 23, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced a significant [...]
Pfizer et Valneva annoncent que le candidat vaccin contre la maladie de Lyme démontre une forte efficacité dans l’essai de Phase 3 VALOR
23/03/2026
Le candidat vaccin PF-07307405 (LB6V) a démontré une efficacité de plus de 70 % dans la prévention de la maladie de Lyme chez les personnes âgées de cinq ans et plus. Le candidat vaccin a été bien toléré, sans problème [...]
Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease
23/03/2026
New data show brain-volume preservation correlates with patient outcomes Long-term clinical data indicate 77.4 weeks (17.8 months) time saved with oral blarcamesine compared to ADNI 1 control group after 144 weeks (33.1 [...]
BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions
23/03/2026
PALO ALTO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced [...]
Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement
23/03/2026
Shareholders are Recommended to Vote “FOR” the Aptose Biosciences Proposed Plan of Arrangement with Hanmi Pharmaceutical Shareholders are Reminded of Voting Deadline for Upcoming Special Meeting SAN DIEGO and TORONTO, [...]
Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
23/03/2026
Enlivex’s first regulatory approval for a late-stage global Phase 2b study in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis following the implementation of its dual-engine value creation model: A clinical- [...]
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
23/03/2026
LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders Lexicon has earned a second of three potential $10 million near- [...]
Theriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma
23/03/2026
– Successful meeting with FDA enables advancement into proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of metastatic PDAC – – Combined feedback from [...]
Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results
23/03/2026
Conference Call and Live Webcast Scheduled for March 26, 2026 PURCHASE, N.Y., March 23, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing product candidates that [...]

Pages